Capricor Therapeutics, Inc. - Common Stock (CAPR)

Capricor Therapeutics (NASDAQ:CAPR) said its biologics license application for deramiocel remains under U.S. Food and Drug Administration review, while the company prepares to submit an amendment seeking a refined indication centered on upper limb skeletal muscle function in Duchenne muscular dystro

Gainers Akanda (NASDAQ:AKAN) stock rose 109.4% to $10.49 during Thursday's after-market session. The company's market cap stands at $2.9 million. Capricor Therapeutics (NASDAQ:CAPR) stock moved upwards by

Capricor Therapeutics (NASDAQ:CAPR) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For

Focused on rare disease therapeutics, this biotech firm reported a notable insider sale amid a year of substantial stock gains.

Capricor Therapeutics (NASDAQ:CAPR) executives said the company is in active discussions with the U.S. Food and Drug Administration as it works toward a potential approval decision for deramiocel, its allogeneic cardiac-derived cell therapy for Duchenne muscular dystrophy. Speaking at a Goldman Sac

Capricor (CAPR) Q1 2026 Earnings Transcript

Capricor Therapeutics (NASDAQ:CAPR) said its Duchenne muscular dystrophy therapy candidate deramiocel remains under active FDA review, while the company is preparing to commercialize the product itself amid a legal dispute with distribution partner NS Pharma and parent company Nippon Shinyaku. On t

Focused on advanced cell therapies for rare diseases, this biotech firm reported a notable insider sale in its latest SEC filing.

On the company’s fourth-quarter (Q4) earnings call on Thursday, CEO Linda Marban rejected the possibility that the Deramiocel therapy could receive only a conditional approval.

The FDA has accepted Capricor’s resubmitted biologics license application, setting an Aug. 22 PDUFA decision date for Deramiocel in DMD.

Capricor (CAPR) Q4 2025 Earnings Call Transcript

For the fourth quarter, the company reported a net loss of $0.62 per share, compared to loss of $0.16 per share in the corresponding quarter of 2024.

The update comes as the therapy’s regulatory application awaits a decision from the U.S. Food and Drug Administration later this year.